{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:38:10Z","timestamp":1788482290664,"version":"build-2803163510"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0186235","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T13:53:34Z","timestamp":1507816414000},"page":"e0186235","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-4312","authenticated-orcid":true,"given":"Steven","family":"Sparagana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy A.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Bissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Burock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Christopher","family":"Kingswood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"JP Osborne","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"DN Franz","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1038\/sj.onc.1209090","article-title":"Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease","volume":"24","author":"A Astrinidis","year":"2005","journal-title":"Oncogene"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","author":"European Chromosome","year":"1993","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","volume":"277","author":"M van Slegtenhorst","year":"1997","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/hmg\/7.6.1053","article-title":"Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products","volume":"7","author":"M van Slegtenhorst","year":"1998","journal-title":"Hum Mol Genet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)","volume":"277","author":"EA Goncharova","year":"2002","journal-title":"J Biol Chem"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"K Inoki","year":"2002","journal-title":"Nature Cell Biology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"J Huang","year":"2008","journal-title":"Biochem J"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"DN Franz","year":"2013","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Final long-term results from EXIST-2","volume":"31","author":"JJ Bissler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ana.24523","article-title":"Everolimus for subependymal giant cell astrocytoma: 5-year final analysis","volume":"78","author":"DN Franz","year":"2015","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease","volume":"6","author":"SL Dabora","year":"2011","journal-title":"PLoS One"},{"key":"ref14","unstructured":"Novartis Pharmaceutical Corporation. Prescribing information for Afinitor (everolimus) tablets for oral administration. Afinitor Disperz (everolimus tablets for oral suspension). Updated June 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/afinitor.pdf\" xlink:type=\"simple\">https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/afinitor.pdf<\/ext-link>. Accessed 12 January 2017."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.tem.2010.05.003","article-title":"Energy balance and puberty onset: emerging role of central mTOR signaling","volume":"21","author":"J Roa","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1210\/en.2005-0337","article-title":"Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by kisspeptin in undernutrition","volume":"146","author":"JM Castellano","year":"2005","journal-title":"Endocrinology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1210\/en.2009-0096","article-title":"The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system","volume":"150","author":"J Roa","year":"2009","journal-title":"Endocrinology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"JJ Bissler","year":"2013","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial","volume":"31","author":"JJ Bissler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"DA Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/1933719114542016","article-title":"Caloric restriction promotes the reserve of follicle pool in adult female rats by inhibiting the activation of mammalian target of rapamycin signaling","volume":"22","author":"L Li","year":"2015","journal-title":"Reprod Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"19431","DOI":"10.1074\/jbc.M401235200","article-title":"Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase\/AKT\/Ras homolog enriched in brain (Rheb)\/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation","volume":"279","author":"H Alam","year":"2004","journal-title":"J Biol Chem"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12020-016-1065-8","article-title":"HCG-mediated activation of mTORC1 signaling plays a crucial role in steroidogenesis in human granulosa lutein cells","volume":"54","author":"MB Moravek","year":"2016","journal-title":"Endocrine"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1432-2277.2006.00423.x","article-title":"Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview","volume":"20","author":"E Huyghe","year":"2007","journal-title":"Transpl Int"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2005.00257.x","article-title":"The effect of sirolimus on sex hormone levels of male renal transplant recipients","volume":"19","author":"S Lee","year":"2005","journal-title":"Clin Transplant"},{"key":"ref26","article-title":"Common terminology criteria for adverse events (CTCAE) version 4.03","year":"2010"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0186235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:27:22Z","timestamp":1540340842000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0186235"}},"subtitle":[],"editor":[{"given":"James","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0186235","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}